Ex Parte 5955106 et al - Page 6

                Appeal No.  2006-3234                                                                           
                Application No.  90/006,410                                                                     

                                                      Abdallah                                                  
                       18. Abdallah discloses controlled release metformin tablets                              
                             containing methyl cellulose made using coprecipitation                             
                             technique. (Abdallah at 16).                                                       
                       19. Alkyl celluloses, including methyl cellulose particularly, are                       
                             disclosed and claimed as “hydrocolloid forming retarding                           
                             agents” in the ‘106 patent.  (‘106 at 3:20-33 and e.g., claims 6                   
                             and 7).                                                                            
                       20. Abdallah reports that methyl cellulose is “a hydrophilic                             
                             polymer” and a “hydrocolloid” (Abdallah at 18).                                    
                       21.  Abdallah does not disclose the residual moisture content of its                     
                             prepared tablets.                                                                  
                                                        Otaya                                                   
                       22.  The examiner rejected claims 34-36, 60, 61, 95, 98, 99 and                          
                             123-126 under 35 USC § 103(a) as being obvious over                                
                             Abdallah, Evenstad, and Otaya.  (Answer at 7).                                     
                       23. Appellants do not argue any of these rejected claims, which                          
                             primarily recite limitations regarding capping, separately from                    
                             any other rejected claim.                                                          
                       24. Claim 35, for example, reads as follows:                                             
                       The composition of claim 1, wherein compression of the                                   
                             admixture into tablets is without large losses from                                
                             capping.                                                                           
                       25. An “object” of the ‘106 invention is to “solve the problem of                        
                             capping.” (‘106 at 1:52-55).                                                       


                                                       6                                                        

Page:  Previous  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  Next

Last modified: September 9, 2013